A MECC-Organized Symposium at the ATS 2026 International Conference. An evening symposia educational program sponsored by Med Learning Group and supported by a grant from GSK open to all ATS 2026 International Conference attendees.
Monday, May 18, 2026
6:30 PM – 6:45 PM ET Registration & Dinner
6:45 PM – 8:15 PM ET CE Symposium
Hilton Orlando
6001 Destination Parkway
Orlando, Florida 32819
Meeting Location: Orange Ballroom D–G
PROGRAM FEATURES
• Interactive case-based presentation
• Downloadable whiteboard animations
• Online personalized quality-improvement poster-generation portal
PRESENTING FACULTY
 |
Stephanie Christenson, MD, MAS Associate Professor Division of Pulmonary, Critical Care, & Sleep Medicine University of California, San Francisco San Francisco, California |
 |
Gerard J. Criner, MD, FACP, FACCP Professor and Founding Chair Department of Thoracic Medicine and Surgery Lewis Katz School of Medicine at Temple University Philadelphia, Philadelphia |
PROGRAM OVERVIEW
This satellite symposium is designed for pulmonologists and advanced practice providers who care for patients with chronic obstructive pulmonary disease (COPD). The program will explore the underlying pathophysiology of COPD, with a particular focus on the role of type 2 inflammatory pathways in disease development and progression.
Participants will gain insights into how disease phenotypes, biomarkers, and treatable traits can inform a COPD diagnosis and guide individualized treatment planning. The symposium will also emphasize the importance of aligning treatment decisions with clinical guidelines while incorporating the patient perspective and fostering multidisciplinary collaboration to optimize care.
TARGET AUDIENCE
This educational activity is intended for pulmonologists and pulmonology advanced practice providers involved in the care of patients with COPD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- SUMMARIZE the pathophysiologic mechanisms, including the role of type 2 inflammatory pathways, underlying COPD development and progression
- INCORPORATE disease phenotypes, biomarkers, and treatable traits into COPD diagnostic and treatment planning discussions
- CONSTRUCT guideline-informed COPD treatment plans that integrate the patient perspective and multidisciplinary care
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
